Daridorexant
- TRADE NAME: Quvivo (Idorsia)
- INDICATIONS: Insomnia
- CLASS: Orexin receptor antagonist
- HALF-LIFE: approximately 8 hours
FDA APPROVAL DATE: 01/07/2022
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:CYP3A4 inducers, CYP3A4 inhibitors, Diltiazem, Efavirenz, Itraconazole, Ranitidine, Ranitidine, Rifampin
No available data on daridorexant use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.
CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. Risk increases when used with other central nervous system depressants. Avoid alcohol consumption with daridorexant.
Please login to see the rest of this drug profile
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
RESPIRATORY.
Page last updated 04/27/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
